Teriparatide + Placebo
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Fractures
Conditions
Fractures
Trial Timeline
Jul 1, 2010 → Apr 1, 2014
NCT ID
NCT01173081About Teriparatide + Placebo
Teriparatide + Placebo is a approved stage product being developed by Eli Lilly for Fractures. The current trial status is unknown. This product is registered under clinical trial identifier NCT01173081. Target conditions include Fractures.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03072147 | Phase 2 | Completed |
| NCT01473589 | Phase 3 | Completed |
| NCT01473602 | Phase 3 | Completed |
| NCT01292252 | Approved | Completed |
| NCT01279187 | Phase 2 | Terminated |
| NCT01173081 | Approved | UNKNOWN |
| NCT00433160 | Phase 3 | Completed |
| NCT00190944 | Phase 2 | Completed |
Competing Products
12 competing products in Fractures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK5211 + Placebo | Viking Therapeutics | Phase 2 | 47 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 77 |
| Zoledronic Acid 5Mg/Bag 100Ml Inj + sodium chloride | Roche | Approved | 85 |
| Denosumab 70 mg/mL + Zoledronic acid 4 mg + Placebo IV + Placebo SC | Amgen | Phase 3 | 76 |
| rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM | Pfizer | Phase 2/3 | 64 |
| rhBMP-2/CPM | Pfizer | Phase 2 | 51 |
| InductOs | Pfizer | Approved | 84 |
| rhBMP-2/CPM | Pfizer | Phase 1 | 32 |
| rhBMP-2/CPM + rhBMP-2/CPM | Pfizer | Phase 2 | 51 |
| Tranexamic Acid plus standard of care | Pfizer | Approved | 84 |
| CP-533, 536 + Placebo + CP-533,536 + CP-533,536 + CP-533,536 | Pfizer | Phase 2 | 51 |
| enoxaparin (XRP4563) | Sanofi | Phase 3 | 76 |